Lori Anne Kunkel

Executive

Oric Pharmaceuticals, Inc.Nurix Therapeutics, Inc.Enliven Therapeutics, Inc.

Insider activity · 24 months0 buys5 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 3 salesJul 26 · 0 buys · 2 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (5 ops.)

€739k

Latest filing published 08 Jul 2026 for Enliven Therapeutics, Inc., €180k. Read the official filing

Filing timeline

BuySale

Lori Anne Kunkel

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Lori Anne Kunkel: trading record in brief

Lori Anne Kunkel discloses dealings in 3 companies, chiefly Enliven Therapeutics, Inc., Oric Pharmaceuticals, Inc. and Nurix Therapeutics, Inc. The record holds 11 filings, for trades running from 3 June 2024 to 6 July 2026.

The open-market record consists of 5 sales worth €739k, with no purchase. The rest of the record consists of 5 option exercises. In 2026 alone, the filings show no purchases and 5 sales.

The latest filing, published on 8 July 2026, reports an open-market sale of €262k in Enliven Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.